Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2012 Feb 1;35(2):231-6.
doi: 10.5665/sleep.1628.

Glucose tolerance in patients with narcolepsy

Pierre A Beitinger  1 , Stephany Fulda, Mira A Dalal, Renate Wehrle, Marietta Keckeis, Thomas C Wetter, Fang Han, Thomas Pollmächer, Andreas Schuld
Affiliations
Controlled Clinical Trial

Glucose tolerance in patients with narcolepsy

Pierre A Beitinger et al. Sleep. .

Abstract

Study objectives: Obesity is a common feature of narcolepsy. In addition, an increased occurrence of non-insulin dependent diabetes has been reported. So far, it is not known whether glucose metabolism in narcolepsy is disturbed due to, or independently of obesity.

Design: Case-control study.

Setting: Sleep medicine clinic at a research institute.

Patients: We studied 17 patients with narcolepsy/cataplexy compared to 17 healthy controls matched for age, sex, and body mass index (BMI).

Interventions: A 75-g oral glucose tolerance test was performed.

Measurements: Glucose tolerance was determined by computing plasma glucose curve following oral glucose challenge for 240 minutes; insulin sensitivity and insulin secretion by homeostasis model assessment and minimal model analysis.

Results: Standard outcome measures and indices of the oral glucose tolerance test did not differ between the patient group and the group of control subjects.

Conclusions: In this study, no clinically relevant pathologic findings in the glucose metabolism of narcoleptic patients compared to weight matched controls were found. Thus, narcolepsy is unlikely to be a risk factor per se for impaired glucose tolerance or diabetes.

Keywords: Narcolepsy; hypersomnia; hypocretin; metabolism; orexin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean plasma glucose levels in patients with narcolepsy and control participants during the oral glucose tolerance test (OGTT). Error bars represent SD. There were no significant differences between groups in the sample. To convert glucose to mg/dl, multiply by 18.0182.
Figure 2
Figure 2
Mean plasma glucose levels in patients with narcolepsy and matched control participants during the oral glucose tolerance test (OGTT). (A) Orexin deficient patients (4 f, 8 m). (B) Drug free patients (3 f, 6 m). Error bars represent SD. There were no significant differences between groups in the samples. To convert glucose to mg/dl, multiply by 18.0182.
See this image and copyright information in PMC

References

    1. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355:39–40. - PubMed
    1. Dalal MA, Schuld A, Haack M, et al. Normal plasma levels of orexin A (hypocretin-1) in narcoleptic patients. Neurology. 2001;56:1749–51. - PubMed
    1. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypo-cretin neurons in human narcolepsy. Neuron. 2000;27:469–74. - PMC - PubMed
    1. Lin L, Hungs M, Mignot E. Narcolepsy and the HLA region. J Neuroimmunol. 2001;117:9–20. - PubMed
    1. Tsujino N, Sakurai T. Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol Rev. 2009;61:162–76. - PubMed

Publication types